This content is from: Video

Pharmaceuticals Specialty: M&A Activity Will Continue to Drive Investor Interest

Evercore ISI's Umer Raffat, the sector's No. 1 analyst, is unabashedly bullish on speciality pharmaceuticals manufacturers, citing reasonable valuations and a high number of takeover targets.

Video Episode 8